Recent Updates
Recently added Catalysts
VIR Positive Sentiment Score: 65/100

Vir Biotechnology to Participate in the BofA Securities 2023 Health Care Conference

Wednesday, May 3, 2023 1 min read
Key Takeaway: Vir Biotechnology, Inc. has announced its participation in the BofA Securities 2023 Health Care Conference, where CEO Marianne De Backer will present. The presentation is scheduled for May 10 at 8:00 a.m. PT / 11:00 a.m. ET, and investors can access a live webcast on the company's website. Vir Biotechnology is dedicated to developing immunological solutions for serious infectious diseases, with a pipeline targeting multiple viruses.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a prominent healthcare conference highlights visibility.
  • CEO's presentation may attract investor interest and confidence.
  • Vir Biotechnology showcases a strong focus on immunologic health solutions.

Full Press Release Details

SAN FRANCISCO, May 03, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to present at the BofA Securities 2023 Health Care Conference on Wednesday, May 10, at 8:00 a.m. PT / 11:00 a.m. ET.
A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there for 30 days.
About Vir Biotechnology
Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B and D viruses, influenza A and human immunodeficiency virus. Vir routinely posts information that may be important to investors on its website.

Tags

Frequently Asked Questions

When is Vir Biotechnology's presentation at the BofA Conference?

The presentation is scheduled for May 10, 2023, at 8:00 a.m. PT.

Who is presenting on behalf of Vir Biotechnology?

Marianne De Backer, M.Sc., Ph.D., MBA, will present for Vir Biotechnology.

Where can I watch Vir's presentation live?

The live webcast can be accessed on Vir's website under Events & Presentations.

What is the focus of Vir Biotechnology?

Vir Biotechnology focuses on treating and preventing serious infectious diseases.

What diseases does Vir's pipeline target?

Vir's pipeline targets COVID-19, hepatitis B and D, influenza A, and HIV.

Tags: VIR Viatris Investor Conferences Healthcare Vir Biotechnology BofA Securities healthcare conference immunology Marianne De Backer
Last updated: May 3, 2023